AVTR:NYE-Avantor Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 26.88

Change

0.00 (0.00)%

Market Cap

USD 18.27B

Volume

3.07M

Analyst Target

USD 23.81
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-2.77 (-1.18%)

USD 67.65B
ALC Alcon AG

-1.46 (-1.48%)

USD 48.64B
RMD ResMed Inc

-0.89 (-0.35%)

USD 35.98B
BAX Baxter International Inc

-0.45 (-1.12%)

USD 20.54B
TFX Teleflex Incorporated

-4.61 (-1.87%)

USD 11.63B
ATR AptarGroup Inc

+0.04 (+0.03%)

USD 10.16B
BLCO Bausch + Lomb Corp

+0.76 (+4.27%)

USD 6.26B
STVN Stevanato Group SpA

-0.21 (-1.09%)

USD 5.62B
WRBY Warby Parker Inc

-0.12 (-0.80%)

USD 1.57B
INFU InfuSystems Holdings Inc

-0.09 (-1.38%)

USD 0.14B

ETFs Containing AVTR

COPP Sprott Copper Miners ETF 10.10 % 0.00 %

+0.18 (+0.77%)

N/A
CEBS:XETRA iShares Copper Miners UCI.. 7.39 % 0.00 %

+0.04 (+0.77%)

USD 0.04B
GMTL:AU Global X Green Metal Mine.. 5.09 % 0.00 %

+0.03 (+0.77%)

N/A
XMET:AU BetaShares Energy Transit.. 4.93 % 0.00 %

-0.10 (0.77%)

N/A
COPX:SW Global X Copper Miners UC.. 4.56 % 0.00 %

+0.28 (+0.77%)

N/A
D6AT:XETRA Global X Disruptive Mater.. 4.46 % 0.00 %

+0.13 (+0.77%)

N/A
DMAT Global X Disruptive Mater.. 4.31 % 0.00 %

+0.13 (+0.77%)

USD 4.64M
COPX Global X Copper Miners ET.. 4.31 % 0.65 %

+0.14 (+0.77%)

USD 2.06B
COPX:LSE Global X Copper Miners UC.. 4.31 % 0.00 %

+0.26 (+0.77%)

N/A
COPG:LSE Global X Copper Miners UC.. 4.31 % 0.00 %

+0.27 (+0.77%)

USD 0.15B
EXV6:XETRA iShares STOXX Europe 600 .. 3.88 % 0.00 %

+0.43 (+0.77%)

USD 0.37B
M7ES:XETRA HANetf ICAV - Sprott Ener.. 3.71 % 0.00 %

-0.01 (0.77%)

USD 3.87M
SETM:LSE HANetf ICAV - Sprott Ener.. 3.52 % 0.00 %

+0.01 (+0.77%)

USD 3.87M
CRIT Optica Rare Earths & Crit.. 2.45 % 0.00 %

+0.05 (+0.77%)

USD 4.24M
SPMD SPDR Russell Small Cap Co.. 0.67 % 0.06 %

+0.32 (+0.77%)

USD 10.86B
MDY SPDR® S&P MIDCAP 400 ETF.. 0.64 % 0.24 %

+2.91 (+0.77%)

USD 21.50B
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.64 % 0.00 %

+1.39 (+0.77%)

USD 2.07B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.64 % 0.00 %

+1.42 (+0.77%)

USD 1.99B
SPY4:SW SPDR® S&P 400 US Mid Cap.. 0.64 % 0.00 %

+0.45 (+0.77%)

USD 2.12B
ZMID:CA BMO S&P US Mid Cap Index .. 0.64 % 0.00 %

+0.21 (+0.77%)

N/A
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.64 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.64 % 0.00 %

N/A

N/A
IJH iShares Core S&P Mid-Cap .. 0.62 % 0.07 %

+0.31 (+0.77%)

USD 85.42B
BSJO Invesco BulletShares 2024.. 0.00 % 0.42 %

N/A

N/A
IVOO Vanguard S&P Mid-Cap 400 .. 0.00 % 0.15 %

+0.57 (+0.77%)

USD 2.12B
MIDU Direxion Daily Mid Cap Bu.. 0.00 % 1.10 %

+0.84 (+0.77%)

USD 0.09B
MVV ProShares Ultra MidCap400 0.00 % 0.95 %

+0.72 (+0.77%)

USD 0.13B
HYDW Xtrackers Low Beta High Y.. 0.00 % 0.25 %

+0.05 (+0.77%)

USD 0.22B
PQIN 0.00 % 0.00 %

N/A

N/A
UMDD ProShares UltraPro MidCap.. 0.00 % 0.95 %

+0.35 (+0.77%)

USD 0.03B
IESZ:LSE 0.00 % 0.00 %

N/A

N/A
EXV6:F iShares STOXX Europe 600 .. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.74% 74% C 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.74% 63% D 76% C+
Trailing 12 Months  
Capital Gain 22.91% 84% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.91% 84% B 70% C-
Trailing 5 Years  
Capital Gain 75.69% 80% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.69% 80% B- 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 17.84% 84% B 81% B-
Dividend Return 17.84% 84% B 79% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.89% 37% F 18% F
Risk Adjusted Return 36.49% 79% B- 54% F
Market Capitalization 18.27B 71% C- 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector